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At ASTRO’s 2017 Annual Meeting in San Diego, CA, attendees were asked, “What is the most 
important research question that needs to be answered in the next 3-5 years?” This request was 
meant to start a dialogue, promote thoughtful discussion within our professional community, and 
help inform topics for ASTRO workshops and focus meetings. Nearly 100 people responded 
while in attendance at the meeting with responses that varied from, “How can we remove 
barriers so low and middle income countries can have radiation oncology facilities?” to “What is 
the exact role of radiation in stage IV disease in combination with immunotherapy or targeted 
agents to combat resistance development?” to “How can personalized care be better integrated 
into the oncology and radiation oncology clinical space?” 
 
At the end of the meeting, an electronic survey was offered to all attendees, which returned 456 
responses.  Of the responses, 136 were related to immunotherapy or combination of 
immunotherapy and radiotherapy (RT) and 131 were related to genomic influences and targeted 
medicine including personalized/individualized cancer care, dose and fractionation, and cancer 
biology and genomics. Forty-seven were related to advanced imaging and innovations in physics 
and technology, such as real-time and functional imaging, MR-guided RT, and proton and heavy 
ion therapy. Sixty-five were related to new clinical trial design including improving comparative 
effectiveness research, outcomes measures, care delivery, and further developing goals for 
specific disease sites.  Other topics included oligometastatic disease and the abscopal effect, the 
role of computers and big data, radiation side effects, global health, cancer prevention, social 
media, and research funding.  The most commonly referenced cancer treatment sites were 
prostate (21 responses) and breast (18 responses). 
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And so, what would you do with 1 million Gray?  Would you treat 20,000 patients living in a 
developing nation who otherwise wouldn’t have access to radiation services?  Would you treat 
16,667 patients on a clinical trial combining immunotherapy and SBRT to better define and map 
a path to abscopal effect?  Would you bring comprehensively integrated, personalized cancer 
care to every patient who walks through your door?  
 
Given the overwhelmingly positive response to this year’s question, we plan to continue this 
exercise as an annual tradition, albeit with a different “1 Million Gray” question each year. So, at 
the 2018 Annual Meeting, how will you answer the ASTRO Bench to Bedside Question, “What 
is the BIGGEST research discovery that needs to be translated into the clinic RIGHT NOW?”  
Stay tuned and contribute! 
 
 
 
 
 
Table 1: “What is the most important research question that needs to be answered in the next 
3-5 years?” 
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Immunotherapy in combination with radiotherapy  136     (30%)    
Genomic influences and targeted medicine 131     (29%) 
New clinical trial design and comparative effectiveness 65      (14%) 
Advanced imaging and physics innovation 47      (10%) 
Oligometastatic disease, abscopal effect, other 77      (17%) 
  
 
